Sunitinib versus dacarbazine as first-line treatment in patients with metastatic uveal melanoma

被引：0
|
作者：
Sacco, Joseph J.
Nathan, Paul D.
Danson, Sarah
Lorigan, Paul
Nicholson, Steve
Ottensmeier, Christian
Corrie, Philippa
Steven, Neil
Goodman, Andrew
Larkin, James M. G.
Evans, T. R. Jeffry
Kumar, Satish
Coupland, Sarah E.
Silcocks, Paul
Marshall, Ernie
机构：
[1] Clatterbridge Canc Ctr, Clatterbridge, Merseyside, England
[2] Mt Vernon Canc Ctr, Northwood, Middx, England
[3] Weston Pk Hosp, Canc Res Ctr, Sheffield, S Yorkshire, England
[4] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England
[5] Charing Cross Hosp, London, England
[6] Southampton Univ Hosp NHS Fdn Trust, Southampton, Hants, England
[7] Addenbrookes Hosp, Ctr Oncol, Cambridge, England
[8] Queen Elizabeth Hosp, Birmingham B15 2TH, W Midlands, England
[9] Royal Devon & Exeter Hosp, Exeter EX2 5DW, Devon, England
[10] Royal Marsden Hosp NHS Fdn Trust, London, England
[11] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[12] Velindre Canc Ctr, Cardiff, S Glam, Wales
[13] Univ Liverpool, Dept Mol & Clin Canc Med, Inst Translat Med, Liverpool L69 3BX, Merseyside, England
[14] Univ Liverpool, Liverpool L69 3BX, Merseyside, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9031
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Sunitinib still first-line therapy for metastatic renal cancer
    Bagcchi, Sanjeet
    LANCET ONCOLOGY, 2014, 15 (10): : E420 - E420
  • [32] Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma
    Remak, Edit
    Charbonneau, Claudie
    Negrier, Sylvie
    Kim, Sindy T.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (24) : 3995 - 4000
  • [33] Sunitinib in combination with folfiri as first-line treatment for metastatic CRC: A phase I study
    Carrato, A.
    Starting, N.
    Vazquez, F.
    Hill, P.
    Lechuga, M.
    Brega, N.
    Chao, R.
    Cunningham, D.
    ANNALS OF ONCOLOGY, 2007, 18 : VII29 - VII29
  • [34] ECONOMIC EVALUATION OF SUNITINIB AS FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA IN COLOMBIA
    Prieto, V. A.
    Reyes, J. M.
    Lopez-Cabra, C.
    Diaz, J. A.
    Urrego-Novoa, J. R.
    VALUE IN HEALTH, 2016, 19 (03) : A149 - A149
  • [35] Economic evaluation of sunitinib as first-line treatment for metastatic renal cell carcinoma in Mexico
    Emilio, Mucino-Ortega
    Joaquin Federico, Mould-Quevedo
    GACETA MEXICANA DE ONCOLOGIA, 2010, 9 (02): : 48 - 57
  • [36] Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC)
    Figlin, R. A.
    Hutson, T. E.
    Tomczak, P.
    Michaelson, M. D.
    Bukowski, R. M.
    Negrier, S.
    Huang, X.
    Kim, S. T.
    Chen, I.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [37] Comparative efficacy of dabrafenib plus trametinib versus treatment options for metastatic melanoma in first-line settings
    Wu, Jing
    Das, Jaydeep
    Kalra, Manik
    Ratto, Barbara
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (04) : 267 - 280
  • [38] Cost-effectiveness analysis of anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma in China
    Lin, Jingyang
    Fang, Qingxia
    Zheng, Xiaochun
    PLOS ONE, 2023, 18 (02):
  • [39] Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial
    Zhou, Ai-Ping
    Bai, Yuxian
    Song, Yan
    Luo, Hong
    Ren, Xiu-Bao
    Wang, Xiuwen
    Shi, Benkang
    Fu, Cheng
    Cheng, Ying
    Liu, Jiyan
    Qin, Shukui
    Li, Jun
    Li, Hanzhong
    Bai, Xianzhong
    Ye, Dingwei
    Wang, Jinwan
    Ma, Jianhui
    ONCOLOGIST, 2019, 24 (08): : E702 - E708
  • [40] Sorafenib versus sunitinib as first-line treatment in metastatic renal cell carcinoma: Largest multicenter retrospective analysis.
    Sheng, Xinan
    Zhang, Hailiang
    Li, Xuesong
    Chi, Zhihong
    He, Zhisong
    Ye, Dingwei
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
12345